The CCR2 inflammatory pathway is a target for improving severe disease and pulmonary inflammation in experimental COVID-19
Yvette Kazungu, Shrilakshmi Hegde, Parul Sharma, Amy E. Marriott, Andrew Steven, Jesús Reiné, Jessica L Dagley, Matthias Mack, Anja Kipar, James P. Stewart, Joseph D. Turner
This study shows that targeting the CCR2 inflammatory pathway reduces severe disease and pulmonary inflammation in a mouse model of SARS-CoV2 infection.
Virulence · Jul 15, 2026Peer-reviewedImmunology